Abstract: Transdermal delivery systems for delivery of Alzheimer's pharmaceuticals, particularly donepezil, over one to seven days are disclosed which deliver the free-base form of the Alzheimer's pharmaceutical at a skin permeation rate such that blood levels of the Alzheimer's pharmaceuticals are comparable to the approved oral dosage forms.